Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 652-660

  Ghosh, Priyanka ^a,b   Brogden, Nicole K ^a   Stinchcomb, Audra L ^a,b,c  

^a University of Kentucky   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c AllTranz Inc   (United States)

Author keywords

Controlled release delivery; Fluvastatin; Formulation vehicle; Microneedles; Pharmacokinetics; Pore lifetime; Spectroscopy; Transdermal drug delivery; Transepidermal water loss

Indexed keywords

FLUINDOSTATIN; NALTREXONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG DIFFUSION; GEL; HAIRLESS GUINEA PIG; MAXIMUM PLASMA CONCENTRATION; MICRONEEDLE; MICROPORE FILTER; NONHUMAN; SKIN IRRITATION; STRATUM CORNEUM; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; YUCATAN MICROPIG;

CONTROLLED RELEASE/DELIVERY; FLUVASTATIN; FORMULATION VEHICLE; MICRONEEDLES; PHARMACOKINETICS; PORE LIFETIME; SPECTROSCOPY; TRANSDERMAL DRUG DELIVERY; TRANSEPIDERMAL WATER LOSS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORING AGENTS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG DELIVERY SYSTEMS; FATTY ACIDS, MONOUNSATURATED; GUINEA PIGS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; IRRITANTS; NALTREXONE; NARCOTIC ANTAGONISTS; NEEDLES; POROSITY; SKIN; SKIN ABSORPTION; SWINE; SWINE, MINIATURE;

EID: 84895918392     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23844     Document Type: Article

References (40)

1. Flynn GL. 1996. Cutaneous and transdermal delivery: Processes and systems of delivery. 3rd ed. Dekker, New York: Modern Pharmaceutics.
2. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. 2010. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 1:109-131.
3. Elias PM, Tsai J, Menon GK, Holleran WM, Feingold KR. 2002. The potential of metabolic interventions to enhance transdermal drug delivery. J Investig Dermatol Symp Proc 7:79-85.
4. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. 1996. Metabolic approaches to enhance transdermal drug delivery.1. Effect of lipid synthesis inhibitors. J Pharm Sci 85:643-648.
5. Harris IR, Farrell AM, Grunfeld C, Holleran WM, Elias PM, Feingold KR. 1997. Permeability barrier disruption coordinately regulates mRNA levels for key enzymes of cholesterol, fatty acid, and ceramide synthesis in the epidermis. J Investig Dermatol 109:783-787.
6. Menon GK, Feingold KR, Elias PM. 1992. Lamellar body secretory response to barrier disruption. J Investig Dermatol 98:279-289.
7. Grubauer G, Feingold KR, Harris RM, Elias PM. 1989. Lipid content and lipid type as determinants of the epidermal permeability barrier. J Lipid Res 30:89-96.
8. Prausnitz MR. 2004. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581-587.
9. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115-124.
10. Prausnitz MR, Langer R. 2008. Transdermal drug delivery. Nat Biotechnol 26:1261-1268.
11. Davis SP, Martanto W, Allen MG, Prausnitz MR. 2005. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng 52:909-915.
12. Gill HS, Prausnitz MR. 2007. Coated microneedles for transdermal delivery. J Control Release 117:227-237.
13. Henry S, McAllister DV, Allen MG, Prausnitz MR. 1998. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci 87:922-925.
14. Martanto W, Moore J, Kashlan O, Kamath R, Wang P, O'Neal J, Prausnitz M. 2006. Microinfusion using hollow microneedles. Pharm Res 23:104-113.
15. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. 2008. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci USA 105:2058-2063.
16. Daddona P, Matriano J, Mandema J, Maa YF. 2011. Parathyroid hormone (1-34)-coatedmicroneedle patch system:Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 28:159-165.
17. Zhang Y, Brown K, Siebenaler K, Determan A, Dohmeier D, Hansen K. 2012. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res 29:170-177.
18. Banks S, Paudel K, Brogden N, Loftin C, Stinchcomb A. 2011. Diclofenac enables prolonged delivery of naltrexone through microneedletreated skin. Pharm Res 28:1211-1219.
19. Gupta J, Gill HS, Andrews SN, Prausnitz MR. 2011. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release 154:148-155.
20. Kalluri H, Banga A. 2011. Formation and closure of microchannels in skin following microporation. Pharm Res 28:82-94.
21. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. 2010. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci 99:3072-3080.
22. Brogden NK. 2012. Clinical evaluation of novel methods for extending microneedle pore lifetime. PhD. Thesis University of Kentucky.
23. Grubauer G, Elias PM, Feingold KR. 1989. Transepidermal water loss: The signal for recovery of barrier structure and function. J Lipid Res 30:323-333.
24. Micromedex2.0. Accessed July 1, 2013, at: http://www.micromedexsolutions. com/micromedex2/librarian.
25. Vivitrol. Alkermes. Accessed July 1, 2013, at: http://www.vivitrol.com/.
26. Revia. Accessed July 1, 2013, at: http://www.rxlist.com/reviadrug.htm.
27. Mao-Qiang M, Feingold KR, Thornfeldt CR, Elias PM. 1996. Optimization of physiological lipid mixtures for barrier repair. J Investig Dermatol 106:1096-1101.
28. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. 2005. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci 94:1965-1975.
29. Milewski M. 2011. Microneedle-assisted transdermal delivery of naltrexone species: In vitro permeation and in vivo pharmacokinetic studies. PhD. Thesis. Lexington, Kentucky: University of Kentucky.
30. Milewski M, Stinchcomb A. 2011. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res 28:124-134.
31. Andersen F, Hedegaard K, Petersen TK, Bindslev-Jensen C, Fullerton A, Andersen KE. 2006. The hairless guinea-pig as a model for treatment of cumulative irritation in humans. Skin Res Technol 12: 60-67.
32. Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. 2012. Diclofenac delays micropore closure following microneedle treatment in human subjects. J Control Release 163:220-229.
33. Brogden N, Banks S, Crofford L, Stinchcomb A. 2013. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharm Res 30:1947-1955.
34. Ghosh P, Pinninti RR, Hammell DC, Paudel KS, Stinchcomb AL. 2013. Development of a codrug approach for sustained drug delivery across microneedle-treated skin. J Pharm Sci 102:1458-1467.
35. Ghosh P. 2013. Formulation optimization for pore lifetime enhancement and sustained drug delivery across microneedle treated skin. PhD. Thesis. Lexington, Kentucky: University of Kentucky.
36. American Chemical Society. Accessed July 1, 2013. www.scifinder.cas.org.
37. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. 1990. Percutaneous absorption enhancement of an ionic molecule by ethanol- water systems in human skin. Pharm Res 7:762-766.
38. Barry BW. 1987. Mode of action of penetration enhancers in human skin. J Control Release 6:85-97.
39. Thong HY, Zhai H, Maibach HI. 2007. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol 20:272-282.
40. Arora A, Kisak E, Karande P, Newsam J, Mitragotri S. 2010. Multicomponent chemical enhancer formulations for transdermal drug delivery: More is not always better. J Control Release 144:175-180.